The DIGICORE Breast Cancer Working Group is currently performing a multinational study to better characterize the real world natural history of metastatic HR positive HER2 negative breast cancer. By transforming institutional data into the OMOP common data model and running analyses through a federated research network, the consortium can generate harmonized evidence across countries without moving sensitive patient level data. This approach enables consistent, reproducible analytics while fully respecting local governance and privacy constraints.

The study explores how patients are treated across successive lines of therapy, how clinical and molecular factors shape treatment choices, and how real world outcomes evolve over time. It also examines access to targeted therapies, patterns of re biopsy, timing of treatment transitions, and care near the end of life.

Through federated OMOP based collaboration, DIGICORE can answer questions that no single center could address alone—revealing practice variation, identifying unmet needs, and building the evidence base required to improve and personalize care for patients across Europe.